挪威儿童急性淋巴细胞白血病的中等剂量甲氨蝶呤治疗。一项全国治疗方案报告。
Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukaemia in Norway. Report on a national treatment program.
作者信息
Moe P J, Seip M, Finne P H
出版信息
Haematologia (Budap). 1981;14(3):257-63.
PMID:6948760
Abstract
Three courses of intermediate dose methotrexate, 500 mg/m2 at three weekly intervals have been used as part of sanctuary therapy to 95 out of 112 children with acute lymphocytic leukaemia in Norway in the period August 1975 to December 1979. Eight doses of MTX IT were also used for CNS prophylaxis, the first dose was given on the day of admission. As of July 1, 1980, 75 out of 95 (79%) were still in CCR for a median of 36 months (6-57 months).
摘要
1975年8月至1979年12月期间，挪威对112名急性淋巴细胞白血病患儿中的95名采用了三个疗程的中等剂量甲氨蝶呤治疗，剂量为500 mg/m²，每三周一次，作为庇护所治疗的一部分。还使用了八剂鞘内注射甲氨蝶呤进行中枢神经系统预防，第一剂在入院当天给药。截至1980年7月1日，95名患儿中有75名（79%）仍处于持续完全缓解状态，中位缓解时间为36个月（6 - 57个月）。
Zotero 插件